Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 25Breast 4Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 3Uveal Melanoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Paclitaxel 2Nivolumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Carboplatin 2veliparib 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1Topotecan 1Temozolomide 1Taxes 1Specimen Handling 1Ramucirumab 1Quality of Life 1Polymerase Chain Reaction 1Pemetrexed 1Patient Reported Outcome Measures 1Paracentesis 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × olaparib × Dermatologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡